Introduction {#sec1_1}
============

Performance status (PS) is a strong independent prognostic factor for survival in patients with advanced gastric cancer \[[@B1], [@B2]\]. In general, patients selected for participation in clinical trials are required to have an Eastern Cooperative Oncology Group (ECOG) PS =2. In fact, the majority of patients in cancer clinical trials have an ECOG PS 0-1, with less than 10% having a PS 2. Few clinical trials targeting ECOG PS 3 or 4 gastrointestinal cancer patients have been reported \[[@B3], [@B4]\]; thus, such patients are not generally considered to be candidates for chemotherapy. According to the US National Comprehensive Cancer Network (NCCN) clinical practice guidelines for gastric cancer \[[@B5]\], patients with an ECOG PS 3-4 should only be offered best supportive care. Despite these recommendations, some gastric cancer patients in clinical practice with a deteriorated PS wish to receive chemotherapy. Here we report a case of an advanced gastric cancer patient with poor PS (ECOG PS 4) whose PS improved with chemotherapy and radiotherapy.

Case Presentation {#sec1_2}
=================

A 63-year-old Japanese male was admitted to our hospital with worsening dyspnea, cough and anorexia for 1 month. He also had noticed bilateral leg paralysis for 2 weeks. One year before admission, he was diagnosed as having gastric cancer with pathological evidence of a poorly-differentiated adenocarcinoma for which he refused to undergo any surgical or medical treatment. On admission, his physical examination was notable for decreased respiratory sounds in bilateral lower lungs. His oxygen saturation was 86% on room air and 96% with 2 l/min oxygen administration. He also demonstrated bilateral leg weakness. Chest X-ray on admission showed an enlarged cardiac silhouette, with a cardiothoracic ratio of 60%. His laboratory results were notable for increased serum liver enzymes (aspartate transaminase 1,149 IU/l, alanine transaminase 965 IU/l, lactate dehydrogenase 1,580 IU/l). Echocardiography showed pericardial effusions with triphasic flow with increased retrograde amplitude in the inferior vena cava on duplex Doppler sonogram, which was suspected to be caused by increased right heart pressure during the cardiac cycle. Therefore, emergent pericardiocentesis was performed, and the drainage tube was left in the pericardial space. The total volume of effusions was approximately 500 ml at day 1, 300 ml at day 2 and 200 ml at day 3. Malignant adenocarcinoma cells were detected in cytologic analysis of the effusion. Although his liver dysfunction was improved by pericardial drainage, his dyspnea worsened, which required increment of O~2~ administration (5 l). A computed tomography (CT) scan showed extensive infiltration of the lung and bilateral pleural effusions, compatible with lymphangitic carcinomatosis ([fig. 1a, b](#F1){ref-type="fig"}). Abdominal CT scan showed para-aortic lymph node metastasis and ascites ([fig. 2a, b](#F2){ref-type="fig"}). Bone scan revealed multiple bone metastases at cervical and thoracic vertebrae (C7 to Th7). Although he had PS 4 with dyspnea requiring oxygen administration, he strongly wished to receive chemotherapy. Therefore, combination therapy consisting of 5-fluorouracil (5-FU) and leucovorin (LV) was initiated. The dose and administration schedule were planned as follows: infusional 5-FU (250 mg/m^2^) in 24 h and LV (25 mg/m^2^) in 1 h, on days 1-14 every 21 days. Although his respiratory status was transiently worsened and oxygen administration was increased to 7 l on day 3 ([fig. 3a](#F3){ref-type="fig"}), it improved thereafter, and oxygen administration was discontinued at day 14. Because his leg weakness worsened soon after the initiation of chemotherapy, radiotherapy for bone metastasis (total 30 Gy) was also performed. The amount of pericardial effusions from the drainage tube decreased to 100 ml/day at the end of 5-FU plus LV treatment, and the catheter was removed after intracavitary treatment with a 30 mg bolus of cisplatin. His course was complicated by grade 2 stomatitis secondary to the chemotherapy; this improved within 1 week. His oral intake improved concurrent with the improvement of PS, and chemotherapy using oral fluoropyrimidine of S-1 was initiated after completion of infusional chemotherapy, approximately 2 months after his initial presentation. Chest X-ray and CT scan prior to S-1 chemotherapy showed improved extensive lung infiltration and ascites ([fig. 1c, d](#F1){ref-type="fig"}, [2c, d](#F2){ref-type="fig"}, [3b](#F3){ref-type="fig"}). His PS was well maintained (PS 1) with chemotherapy administered on an outpatient basis. However, his tumor returned after 5 months of oral chemotherapy. Although he was treated with second-line chemotherapy using paclitaxel, he passed away 2 months later, approximately 9 months after his initial admission.

Discussion {#sec1_3}
==========

As a result of disease progression, patients with gastric cancer experience several complications, including anorexia, fatigue, abdominal distension and dyspnea, which can lead to deterioration of general patient status. The prognosis of advanced gastric cancer patients, particularly those with an ECOG PS 3-4, is dismally poor. Usually, best supportive care without chemotherapy is offered to these patients \[[@B5]\]. However, according to our previous report \[[@B6]\] which evaluated 116 gastrointestinal cancer patients with PS 3-4 who received chemotherapy (including 37 gastric cancer patients), 32.7% achieved a tumor response, or a decrease in accumulated fluid, or a decline in tumor markers, resulting in a survival benefit compared to the other patients without any effect (6.9 months vs. 2.2 months, p \< 0.001). Also, improvement in the PS for a duration of more than 4 weeks was seen in 13.8% of the patients with a low incidence of toxicity-related death (0.8%). These results and this case report suggest that chemotherapy might be beneficial in some gastric cancer patients, even those with a poor PS. However, the effect of chemotherapy may not be sufficient to achieve an improvement in PS, as evidenced by our use of multimodal therapy in this patient. Therefore, further study might be required to investigate which patients might gain benefit from chemotherapy. For example, gefitinib for patients with lung adenocarcinoma harboring mutation in epidermal growth factor receptor results in PS improvement of 79% and median survival time of 17.8 months even in patients with poor PS \[[@B7]\]. The development of targeted therapies for gastric cancer should also allow the delivery of tailored treatment more adequate for individual patients through molecular profiling of their tumors. Finally, it is important to consider the patient\'s opinion due to the lack of sufficient evidence and the modest improvement in survival obtained with chemotherapy in advanced gastric cancer.

Conclusion {#sec1_4}
==========

Our case suggests that multimodal therapy including chemotherapy may be beneficial in advanced gastric cancer patients even in the setting of poor PS.

Consent {#sec1_5}
=======

Written informed consent was obtained from the patient\'s wife for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

![**a, b** CT scan prior to chemotherapy with 5-FU plus leucovorin. Extensive infiltration of the lung and bilateral pleural effusions are shown, compatible with lymphangitis carcinomatosis. **c**, **d** CT scan prior to chemotherapy with S-1. Lung infiltration and bilateral pleural effusions had nearly disappeared.](cro0003-0262-f01){#F1}

![**a, b** CT scan prior to chemotherapy with 5-FU plus leucovorin. Bilateral pleural effusions, ascites and para-aortic lymph node metastases were seen. Pericardial tube was inserted at apex (white arrowhead). **c**, **d** CT scan prior to chemotherapy with S-1. Bilateral pleural effusions and ascites had nearly disappeared. Para-aortic lymph node metastases were reduced in size.](cro0003-0262-f02){#F2}

![**a** Chest X-ray at day 3 of chemotherapy with 5-fluorouracil and leucovorin, demonstrating extensive infiltration of the lung. **b** Chest X-ray prior to chemotherapy with S-1. Extensive lung infiltration has disappeared.](cro0003-0262-f03){#F3}
